Drug Development

Articles

Pfizer creates separate business units for innovator medicines, generic drugs, and consumer products. 

Pfizer Announces Restructuring

Report predicts PAT, NIRS, continuous bioprocessing, and a ‘technological arms race’ could improve biopharma manufacturing efficiencies.

Cross-Industry Expertise Can Promote Manufacturing Improvements

Biogen will pay Samsung BioLogics approximately $700 million to increase its stake in Samsung Bioepis to approximately 49.9%.

Biogen to Increase Stake in Samsung Bioepis Joint Venture for $700 Million

Bosch Packaging Technology’s GKF 720 capsule filling machine for small batches of hard capsules uses a fully automated, washable containment process.

Capsule Filling Equipment for Small Batches, Highly Potent Drugs

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

After 30 years of biologic-drug advances, the industry and patients still have a lot to learn.

Be Quick, But Don’t Hurry

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Biopharma seeks alternatives that meet the needs for next-gen biologic drug production.

The Search for Next-Gen Expression Systems

With the right excipients, formulators can control when, where, and how an API is released.

Selecting Excipients for Controlled Release

Ronald A. Rader is senior director, Technical Research, at BioPlan Associates.

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

This article highlights 15 years of changes in biopharmaceutical manufacturing.

Fifteen Years of Progress: Biopharmaceutical Industry Survey Results

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

FDA seeks more efficient testing to spur development of less costly biotech therapies.

Biosimilars Raise Manufacturing and Regulatory Challenges

Ronak Savla is scientific affairs manager at Catalent Pharma Solutions.

Claus-Michael Lehr is head of the drug delivery department at the Helmholtz-Institute for Pharmaceutical Research Saarland, SaarbrÃ¼cken, Germany.

Brigitta Loretz is a scientist at Helmholtz-Institute for Pharmaceutical Research Saarland, SaarbrÃ¼cken, Germany.

Olga Hartwig is a PhD student at the Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), SaarbrÃ¼cken, Germany.

William Wei Lim Chin is a technical specialist, science and technology, at Catalent Pharma Solutions.

Macromolecular drugs are typically injected, but oral dosage forms are being developed to improve the treatment of gastrointestinal conditions such as inflammatory bowel disease.

Formulation and Drug Delivery